Annals of lymphoma最新文献_第6页

Sensorineural hearing loss in a patient with follicular lymphoma treated with bendamustine and rituximab 苯达莫司汀和利妥昔单抗治疗滤泡性淋巴瘤患者的感音神经性听力损失

Annals of lymphoma Pub Date : 2019-05-16 DOI: 10.21037/AOL.2019.04.01

Gabrielle Rule, Aaron Esmaili, C. Cheah

引用次数: 0

Venetoclax for the treatment of mantle cell lymphoma Venetoclax治疗套细胞淋巴瘤

Annals of lymphoma Pub Date : 2019-04-15 DOI: 10.21037/AOL.2019.03.02

V. Lin, M. Anderson, D. Huang, A. Roberts, J. Seymour, C. Tam

引用次数: 1

Mantle cell lymphoma pathology update in the 2016 WHO classification 2016年世卫组织套细胞淋巴瘤病理分类更新

Annals of lymphoma Pub Date : 2019-03-18 DOI: 10.21037/AOL.2019.03.01

L. Veloza, Inmaculada Ribera‐Cortada, E. Campo

{"title":"Mantle cell lymphoma pathology update in the 2016 WHO classification","authors":"L. Veloza, Inmaculada Ribera‐Cortada, E. Campo","doi":"10.21037/AOL.2019.03.01","DOIUrl":"https://doi.org/10.21037/AOL.2019.03.01","url":null,"abstract":"Mantle cell lymphoma (MCL) is an aggressive mature B-cell neoplasm genetically characterized by the presence of the t(11;14)(q13;q32) that leads to the constitutive overexpression of cyclin D1. The pathological and biological spectrum of this neoplasm has been expanded in recent years. This improvement in the knowledge of the disease has provided a better understanding of the diverse clinical evolution of the patients. The characterization of cyclin D1-negative MCL has led to the identification of cyclin D2 and D3 translocations as alternative mechanisms in this variant. Two major biological and clinical subtypes of the disease have been recognized, conventional and leukemic non-nodal MCL (nnMCL). MCL derives from CD5+ mature B-cells that have bypassed or experienced the germinal center microenvironment, retain a naive or memory-like epigenetic signature and carry a variable load of somatic mutations in the IGHV region; from truly unmutated to highly mutated, respectively. These two subtypes of tumors also differ in their genomic alterations, and clinical behavior, the conventional MCL (cMCL) being more aggressive than the leukemic nnMCL. This review will focus on the new aspects of the pathology of MCL in the updated 2016 WHO classification and its relevance for the clinical practice.","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84115743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma? 免疫调节药物在套细胞淋巴瘤的治疗中是否有作用?

Annals of lymphoma Pub Date : 2019-01-14 DOI: 10.21037/AOL.2019.01.01

A. Albertsson-Lindblad, M. Jerkeman

{"title":"Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?","authors":"A. Albertsson-Lindblad, M. Jerkeman","doi":"10.21037/AOL.2019.01.01","DOIUrl":"https://doi.org/10.21037/AOL.2019.01.01","url":null,"abstract":"Although survival has improved in patients with mantle cell lymphoma (MCL) during the last two decades, thanks to intensified approach upfront and with anti-CD20 targeted treatment, the disease is still regarded as incurable and for the elderly/unfit patient population, there is need for more tolerable and effective treatment options. Immunomodulatory drugs (IMiDs) have demonstrated activity in MCL and could be regarded as attractive components of combinatory regimens for MCL, in light of their broad spectrum of activity and the potency to synergize with monoclonal antibody treatment. This review focus on the role of lenalidomide (L) as single agent in R/R MCL and in combinatory regimens. To date, one can conclude that L is an active agent in MCL, preferably when combined with anti-CD20 antibody, and may have a role as upfront treatment of elderly/unfit patients. Moreover, regimens including lenalidomide in combination with immunochemotherapy and in chemo-free regimens have shown activity, albeit associated with an increased risk of dose-limiting toxicity in untreated patient populations. Randomized trials evaluating the addition of L upfront, and phase I/II trials on L combined with other novel agents such as BTK- and bcl-2 inhibitors are underway and will further bring insight into the role of IMiDs in MCL.","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89105299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aggressive B-cell lymphomas—from morphology to molecular pathogenesis 侵袭性b细胞淋巴瘤——从形态学到分子发病机制

Annals of lymphoma Pub Date : 2019-01-08 DOI: 10.21037/AOL.2018.12.02

Bo-Jung Chen, F. Fend, E. Campo, L. Quintanilla‐Martinez

{"title":"Aggressive B-cell lymphomas—from morphology to molecular pathogenesis","authors":"Bo-Jung Chen, F. Fend, E. Campo, L. Quintanilla‐Martinez","doi":"10.21037/AOL.2018.12.02","DOIUrl":"https://doi.org/10.21037/AOL.2018.12.02","url":null,"abstract":"The2016 revised World Health Organization (WHO) classification of lymphoidmalignancies recognizes several distinct entities within the group of diffuselarge B-cell lymphoma (DLBCL) characterized by unique clinical and pathologicalfeatures. Nevertheless, diffuse large B-cell lymphoma, not otherwise specified(DLBCL, NOS) is the most common aggressive B-cell lymphoma. In the last 20 yearsour understanding of the genetic changes and biology of DLBCL has increasedtremendously. According to the 2016 WHO classification, the diagnosis of DLBCL,NOS, should include cell of origin (COO); germinal centre B-cell (GCB) oractivated B-cell (ABC)/non-GCB subtypes, because of their different molecularfeatures, biologic behavior, prognosis and treatment. High-grade B-celllymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (i.e., double-hit or triple-hit lymphoma, DHL or THL) as well asHGBL, NOS, are two new categories in the 2016 revised WHO classification thatsubstituted the provisional category of B-cell lymphoma, unclassifiable (BCLU)with features intermediate between DLBCL and Burkitt lymphoma (BL), which wasintroduced in the 2008 WHO classification. The pathogenesis and molecularchanges of BL are better understood and led to the recognition of a newprovisional entity called Burkitt-like lymphoma with 11q aberration. In thisarticle, we will review the progress made in the last years within the mostcommonly encountered aggressive B-cell lymphomas, highlighting the betterunderstanding of the underlying disease mechanisms that eventually might be translatedinto more rational and effective therapeutic strategies. Controversial issuesabout fluorescent in situ hybridization (FISH) for the detection of MYC , BCL2 and BCL6 translocations will be addressed, as well as newmolecular techniques used to improve diagnosis and prognostication inaggressive B-cell lymphomas.","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85128751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Risk stratification of mantle cell lymphoma (MCL) 套细胞淋巴瘤(MCL)风险分层

Annals of lymphoma Pub Date : 2018-12-01 DOI: 10.21037/AOL.2018.12.03

Nora Liebers, P. Dreger, M. Dreyling, S. Dietrich

引用次数: 6

Immunotherapy in non-Hodgkin lymphoma 非霍奇金淋巴瘤的免疫治疗

Annals of lymphoma Pub Date : 2018-12-01 DOI: 10.21037/AOL.2018.12.01

C. Jacobson, P. Armand

引用次数: 0

Diffuse large B-cell lymphoma—who should we FISH? 弥漫性大b细胞淋巴瘤-我们应该检查哪些患者?

Annals of lymphoma Pub Date : 2018-11-01 DOI: 10.21037/aol.2018.11.01

D. Stephens, Sonali M. Smith

{"title":"Diffuse large B-cell lymphoma—who should we FISH?","authors":"D. Stephens, Sonali M. Smith","doi":"10.21037/aol.2018.11.01","DOIUrl":"https://doi.org/10.21037/aol.2018.11.01","url":null,"abstract":"Thepoor prognosis and adverse outcomes following standard chemoimmunotherapy forpatients with high-grade B-cell lymphomas harboring rearrangements of MYC and BCL2 and/or BCL6 (HGBL-DH/TH) is now well-established, withless than 20% estimated long term survival following standard therapies.Fortunately, the frequency of HGBL-DH/TH in unselected aggressive B-celllymphomas is relatively uncommon and estimated at 10% of all cases. Thesedouble- and/or triple-hit lymphomas are often, but not universally, associatedwith a clinically aggressive presentation, high-grade morphologic features, orincreased protein expression of the corresponding genes. However, a substantialnumber of patients have no clear indicators of underlying DH/TH. The paradox ofan exceedingly poor prognosis coupled with a relatively uncommon frequencyraises the practical challenge of determining which patient warrants FISHtesting and is an area of substantial controversy and emerging data. Theclinical consequence of missing HGBL-DH/TH is dire, as these patients arelikely undertreated by standard chemoimmunotherapy (RCHOP). However, in acost-conscious era, routine and widespread testing for biologic determinants ofoutcome may not be appropriate, and a critical appraisal of predictors iswarranted. This review will discuss the clinical implications of theserearrangements in aggressive B-cell lymphomas and the potential clinical, pathologic,or biologic predictors of underlying HGBL-DH/TH biology.","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74572688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A new tool in the cancer immunotherapy toolbox? 癌症免疫治疗工具箱中的新工具?

Annals of lymphoma Pub Date : 2018-03-01 Epub Date: 2018-03-20 DOI: 10.21037/aol.2018.03.01

Xiaosheng Wu, Thomas E Witzig

引用次数: 1

Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation. 基于种族、性别、HIV感染状况和性取向的淋巴瘤差异。

Annals of lymphoma Pub Date : 2017-11-01 Epub Date: 2017-11-17 DOI: 10.21037/aol.2017.11.01

Melody Becnel, Christopher R Flowers, Loretta J Nastoupil

引用次数: 13